Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Phase 2 study of aponermin +kt-decp in patients(pts) with Relapsed/Refractory multiple myeloma and extramedullary disease

View Full Paper
Ask AI
Bookmark
Share

Authors

MLMenghan LiuWLWenjing LiYYYan Yan

Discussion

Loading...

Member takes

Overview

Phase 2 study shows 90% overall response rate in patients with relapsed multiple myeloma and extramedullary disease, suggesting potential for improved safety.

Key Points

  • Efficacy evaluation revealed a 90% overall response rate after two cycles in patients with relapsed multiple myeloma and extramedullary disease.
  • Progression-free survival was not reached at a median follow-up of 7.5 months, highlighting the regimen's effectiveness.
  • Treatment regimen combined aponermin and kt-decp, with radiotherapy used when responses did not reach complete remission.
  • Study underscores safety concerns, with significant adverse events like tumor lysis syndrome and pleural effusion observed.],

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df5chttps://doi.org/10.1182/blood-2025-2280
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of aponermin-carfilzomib-dexamethasone-based regimens for relapsed/refractory multiple myeloma: A Phase 2 prospective multi-center study2025
  2. 2Aponermin combined with carfilzomid-pomalidomide-dexamethasone (KPd) in patients with relapsed or refractory multiple myeloma: A prospective, open-label, multicenter study2025
  3. 3Real-world safety and efficacy of aponermin and daratumumab-based regimens in patients with multiple myeloma2025
  4. 4First results of aponermin(Apo) improving teclistamab (tec)/talquetamab (tal) in patients (pts) with Relapsed/Refractory multiple myeloma (RRMM)2025
  5. 5Early rescue intervention with daratumumab, pomalidomide and dexamethasone (DPd) in high-risk smoldering myeloma (HR-SMM) patients included in the GEM-CESAR treated with carfilzomib, lenalidomide and dexamethasone (KRd)- autologous stem cell transplantation (ASCT)-krd-rd2025 · 2 citations